Technical Analysis for MDNA - Medicenna Therapeutics Corp.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 24.62% | |
| Up 3 Days in a Row | Strength | 24.62% | |
| Gapped Down | Weakness | 24.62% | |
| Crossed Above 20 DMA | Bullish | 26.56% | |
| New Uptrend | Bullish | 26.56% | |
| 180 Bullish Setup | Bullish Swing Setup | 26.56% | |
| Pocket Pivot | Bullish Swing Setup | 26.56% | |
| Wide Bands | Range Expansion | 26.56% | |
| Wide Bands | Range Expansion | 56.77% | |
| Gapped Up | Strength | 56.77% |
| Alert | Time |
|---|---|
| Possible Pocket Pivot | about 6 hours ago |
| Up 2 ATRs | about 6 hours ago |
| 10x Volume Pace | about 6 hours ago |
| 5x Volume Pace | about 6 hours ago |
| 3x Volume Pace | about 6 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 2024-02-12
Medicenna Therapeutics Corp. Description
Medicenna Therapeutics Corp, formerly A2 Acquisition Corp, is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing engineered versions of Interleukin (IL)-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines (ECs). The Company focuses on commercialization EC and Superkines for the treatment of cancer. The Company's IL4 EC is a drug that targets the Bulk Tumor, Cancer Stem Cells and Immunosuppressive Cells of the Tumor Micro-environment. MDNA55 is the Company's lead product. MDNA55 is being studied in clinical trials for treatment of CNS cancers. The Company's MDNA56 and MDNA57 are its IL-4 carrying a human cell killing payload. MDNA56 is being developed for the treatment of hematopoietic cancers expressing the Type 1 IL-4R, whereas MDNA57 is intended to selectively target solid tumors and non-malignant cells of the tumor micro-environment expressing the Type 2 IL-4R.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinic Drug Cancer Medical Specialties Clinical Trial Oncology Clinical Medicine Cancers Tumor Immunotherapy Stem Cells Treatment Of Cancer Cancer Immunotherapy Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.1 |
| 52 Week Low | 0.215 |
| Average Volume | 181,335 |
| 200-Day Moving Average | 0.717 |
| 50-Day Moving Average | 1.488 |
| 20-Day Moving Average | 1.783 |
| 10-Day Moving Average | 1.768 |
| Average True Range | 0.191 |
| RSI (14) | 60.47 |
| ADX | 25.59 |
| +DI | 30.025 |
| -DI | 19.424 |
| Chandelier Exit (Long, 3 ATRs) | 1.528 |
| Chandelier Exit (Short, 3 ATRs) | 1.972 |
| Upper Bollinger Bands | 2.080 |
| Lower Bollinger Band | 1.486 |
| Percent B (%b) | 0.78 |
| BandWidth | 33.324 |
| MACD Line | 0.085 |
| MACD Signal Line | 0.104 |
| MACD Histogram | -0.0185 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.190 | ||||
| Resistance 3 (R3) | 2.173 | 2.077 | 2.150 | ||
| Resistance 2 (R2) | 2.077 | 2.016 | 2.085 | 2.137 | |
| Resistance 1 (R1) | 2.013 | 1.978 | 2.045 | 2.030 | 2.123 |
| Pivot Point | 1.917 | 1.917 | 1.933 | 1.925 | 1.917 |
| Support 1 (S1) | 1.853 | 1.856 | 1.885 | 1.870 | 1.777 |
| Support 2 (S2) | 1.757 | 1.818 | 1.765 | 1.763 | |
| Support 3 (S3) | 1.693 | 1.757 | 1.750 | ||
| Support 4 (S4) | 1.710 |
